Autopsy report · NCT04269395
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
Cause of deathFunding or business
“The study was terminated early as per Sponsor's decision”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 5 months before it stopped.
- 125 participants enrolled.
- Results were posted on the registry 2 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Galderma R&D
- Sponsor type
- Industry
- Conditions
- Keratosis, Actinic
- Interventions
- MAL Cream; Vehicle cream
- Participants
- 125
- Sites
- 53
- Countries
- Puerto Rico, United States
Trials that died the same way
- Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
“The study was terminated by the sponsor” - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
“Study was terminated based on Sponsor decision” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
“This study was terminated by the Sponsor.” - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
“The sponsor decided to terminate the study early” - Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
“Study terminated by the Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.